8-K: VolitionRx Secures $6M in Public Offering

VolitionRx Limited announced the pricing of an underwritten public offering of 11.55 million shares of common stock and accompanying warrants, expecting to raise approximately $6.0 million in gross proceeds.

Summary

• VolitionRx Limited priced an underwritten public offering of 11,550,000 shares of common stock and 11,550,000 accompanying common stock purchase warrants.
• The combined offering price for one share and one warrant is $0.52, with $0.01 allocated to the warrant.
• Each warrant has an exercise price of $0.60 per share, is immediately exercisable, and expires five years from the issuance date (October 14, 2030).
• The company granted the underwriter, Newbridge Securities Corporation, a 30-day option to purchase up to an additional 1,732,500 shares and 1,732,500 warrants to cover over-allotments.
• Gross proceeds are expected to be approximately $6.0 million, assuming no exercise of the underwriter's option and excluding warrant exercises.
• Net proceeds are expected to be approximately $5.4 million after deducting estimated offering expenses and assuming no exercise of the warrants.
• The full exercise of the warrants, assuming no underwriter's option exercise, could generate an additional $6.9 million in gross proceeds.
• Certain directors and officers purchased an aggregate of 254,229 shares and accompanying warrants on the same terms as the public offering.
• The company will issue underwriter warrants to purchase up to 929,775 shares at an exercise price of $0.63 per share, exercisable six months after issuance and expiring five years from the Underwriting Agreement date.
• As of September 30, 2025, the company estimated it had approximately $0.3 million in cash and cash equivalents.

Sentiment

Score: 6

Explanation: The offering successfully raised needed capital for a company with low cash reserves, which is positive for continued operations and development. However, the low offering price and potential dilution, coupled with the existing convertible note obligations, temper the overall positive sentiment. The participation of directors and officers is a good sign.

Positives

• Successfully raised approximately $5.4 million in net proceeds (or $6.0 million gross) through the offering, providing crucial capital.
• Potential for an additional $6.9 million in gross proceeds if all warrants are exercised, offering future funding flexibility.
• Proceeds are earmarked for strategic areas: research and product development, clinical studies, product commercialization, working capital, and potential strategic acquisitions.
• Directors and officers participated in the offering, indicating confidence in the company's prospects and the offering terms.

Negatives

• The offering price of $0.52 per unit (share + warrant) is relatively low, potentially indicating dilution for existing shareholders.
• The company had only approximately $0.3 million in cash and cash equivalents as of September 30, 2025, highlighting a significant need for capital.
• The company agreed to make monthly payments on a Senior Secured Convertible Promissory Note entirely in cash until December 31, 2025, which will consume some of the raised capital.
• Lock-up agreements and restrictions on subsequent equity sales could limit future financing flexibility for a period.

Risks

• Actual results may differ materially from forward-looking statements due to market conditions and the satisfaction of closing conditions related to the proposed public offering.
• Risks identified in the company's SEC filings (Form 10-Q, 10-K, and the prospectus supplement related to the offering) could materially and adversely affect results of operations and stock price.
• No assurance can be given that any of the warrants will be exercised, meaning the potential additional $6.9 million in proceeds is not guaranteed.
• The company's ability to maintain registration of common stock under the Exchange Act is subject to commercially reasonable efforts and may be affected by fundamental transactions.
• The Underwriter Warrants and Underwriter Warrant Shares are subject to significant lock-up restrictions (180 days) under FINRA Rule 5110, limiting their immediate liquidity.

Future Outlook

The company intends to use the net proceeds from the offering for research and continued product development, clinical studies, product commercialization, working capital, and other general corporate purposes, including potential strategic acquisitions. The company will also elect to make monthly payments on its Senior Secured Convertible Promissory Note entirely in cash until December 31, 2025.

Management Comments

• Volition is a multi-national company focused on advancing the science of epigenetics.
• Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.
• Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.
• Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.

Industry Context

VolitionRx Limited operates in the epigenetics industry, focusing on developing and commercializing blood tests for early detection and monitoring of diseases such as cancers and conditions associated with NETosis (e.g., sepsis). This capital raise is intended to fund ongoing research, product development, clinical studies, and commercialization efforts within this specialized diagnostic sector.

Corporate Governance

Related Party Transactions

• Certain directors and officers agreed to purchase an aggregate of 254,229 shares and accompanying warrants in the offering on the same terms offered to the public.

Stakeholder Impact

• Shareholders: Potential dilution from the issuance of new shares and warrants. However, the capital raise provides funding for future growth and operations, which could benefit long-term shareholders.
• Employees: Continued funding for research and development, potentially securing jobs and supporting future growth initiatives.
• Customers/Patients: Funding for product development, clinical studies, and commercialization aims to bring new diagnostic tests to market, benefiting those with life-altering diseases.
• Creditors: The capital raise improves the company's financial liquidity, potentially enhancing its ability to meet obligations, including the Senior Secured Convertible Promissory Note.

Next Steps

• Continue research and product development.
• Conduct clinical studies.
• Proceed with product commercialization.
• Manage working capital and general corporate purposes.
• Potentially pursue strategic acquisitions.
• Make monthly payments on the Senior Secured Convertible Promissory Note entirely in cash until December 31, 2025.
• Maintain listing of Common Stock on the Trading Market and comply with reporting obligations.
• Maintain eligibility of Common Stock for electronic transfer through The Depository Trust Company (DTC).

Key Dates

Recommendation

The successful capital raise provides much-needed funding for VolitionRx's ongoing research, development, and commercialization efforts in the epigenetics space, which is a positive for the company's long-term prospects. The participation of directors and officers in the offering also signals internal confidence. However, the low offering price and the immediate need for capital (evidenced by the low cash balance prior to the offering) suggest underlying financial pressures and potential dilution for existing shareholders. The company's commitment to cash payments for its convertible note until year-end will also consume some of the new capital. Given the speculative nature of early-stage biotech and the dilution, a 'hold' recommendation is appropriate, advising investors to monitor execution of the strategic initiatives funded by this raise and future financial performance.

Keywords

VolitionRx Limited, VNRX, Public Offering, Common Stock, Warrants, Equity Raise, SEC Filing, Underwriting Agreement, Epigenetics, Biotechnology, Financial Health, Capital Raise, Clinical Studies, Product Development